[go: up one dir, main page]

JOP20220055A1 - بروتينات اندماج علاجية - Google Patents

بروتينات اندماج علاجية

Info

Publication number
JOP20220055A1
JOP20220055A1 JOP/2022/0055A JOP20220055A JOP20220055A1 JO P20220055 A1 JOP20220055 A1 JO P20220055A1 JO P20220055 A JOP20220055 A JO P20220055A JO P20220055 A1 JOP20220055 A1 JO P20220055A1
Authority
JO
Jordan
Prior art keywords
fusion proteins
acute
therapeutic fusion
organ
injury
Prior art date
Application number
JOP/2022/0055A
Other languages
English (en)
Inventor
Sebastien Irigaray
Darko Skegro
Marco Villani
Laurent Klein
Karl Welzenbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20220055(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20220055A1 publication Critical patent/JOP20220055A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات اندماج مناسبة للاستخدام كدواء أو أداة بحث. قد تتضمن الاستخدامات العلاجية لبروتينات الاندماج الوقاية أو العلاج من الالتهاب الحاد أو المزمن واضطرابات الأعضاء والأوعية الدموية الدقيقة التي يحثها الجهاز المناعي، على سبيل المثال، إصابة الكلى الحادة، متلازمة الضائقة التنفسية الحادة، تعفن الدم، احتشاء عضلة القلب الحاد، تليف الأنسجة وإصابات الأعضاء الأخرى الناتجة عن إصابة رضحية بالأنسجة.
JOP/2022/0055A 2019-09-06 2020-09-04 بروتينات اندماج علاجية JOP20220055A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06
PCT/IB2020/058250 WO2021044360A1 (en) 2019-09-06 2020-09-04 Therapeutic fusion proteins

Publications (1)

Publication Number Publication Date
JOP20220055A1 true JOP20220055A1 (ar) 2023-01-30

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2022/0055A JOP20220055A1 (ar) 2019-09-06 2020-09-04 بروتينات اندماج علاجية
JOP/2022/0058A JOP20220058A1 (ar) 2019-09-06 2020-09-04 بروتينات اندماج علاجية

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2022/0058A JOP20220058A1 (ar) 2019-09-06 2020-09-04 بروتينات اندماج علاجية

Country Status (21)

Country Link
US (3) US20230220048A1 (ar)
EP (3) EP4025239A1 (ar)
JP (3) JP2022547051A (ar)
KR (3) KR20220058585A (ar)
CN (8) CN118772293A (ar)
AR (2) AR119905A1 (ar)
AU (3) AU2020340618B2 (ar)
BR (2) BR112022003745A2 (ar)
CA (3) CA3152990A1 (ar)
CO (2) CO2022002567A2 (ar)
CR (2) CR20220096A (ar)
CU (2) CU20220016A7 (ar)
EC (2) ECSP22016180A (ar)
IL (3) IL290618A (ar)
JO (2) JOP20220055A1 (ar)
MX (2) MX2022002637A (ar)
PE (2) PE20220401A1 (ar)
PH (2) PH12022550539A1 (ar)
TW (1) TW202122414A (ar)
WO (3) WO2021044361A1 (ar)
ZA (2) ZA202201828B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113301914A (zh) * 2018-10-25 2021-08-24 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法
EP4326307A4 (en) * 2021-04-22 2025-03-05 Biolegend Inc PHOSPHATIDYLSERINE BINDING AGENTS FOR DETECTION AND DEPLETION OF PHOSPHATIDYLSERINE POSITIVE CELLS
KR20230001168A (ko) 2021-06-28 2023-01-04 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
CN119158000A (zh) * 2023-10-25 2024-12-20 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
WO2006122327A2 (en) 2005-05-13 2006-11-16 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor viii and sepsis
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
WO2009064448A1 (en) 2007-11-15 2009-05-22 The Feinstein Institute For Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2701730A4 (en) 2011-04-28 2015-05-27 The Feinstein Inst Medical Res MFG-E8 AND USES THEREOF
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
WO2015025959A1 (ja) 2013-08-23 2015-02-26 独立行政法人理化学研究所 蛍光特性を示すポリペプチド、およびその利用
EP4464332A1 (en) * 2014-03-31 2024-11-20 Hanmi Pharm. Co., Ltd. Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
EP3127314B1 (en) * 2014-03-31 2018-03-14 British Telecommunications public limited company Data communication
WO2015175512A1 (en) * 2014-05-15 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CN118063619A (zh) * 2017-03-02 2024-05-24 诺华股份有限公司 工程化的异源二聚体蛋白质
US11028139B2 (en) 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
CN113301914A (zh) 2018-10-25 2021-08-24 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法

Also Published As

Publication number Publication date
IL290660A (en) 2022-04-01
CN114302896A (zh) 2022-04-08
CA3152990A1 (en) 2021-03-11
BR112022003762A2 (pt) 2022-05-31
WO2021044361A1 (en) 2021-03-11
EP4025238A1 (en) 2022-07-13
AU2020343926A1 (en) 2022-04-07
CR20220089A (es) 2022-03-30
WO2021044360A1 (en) 2021-03-11
TW202122414A (zh) 2021-06-16
US20230265160A1 (en) 2023-08-24
CA3152499A1 (en) 2021-03-11
IL290675A (en) 2022-04-01
JP2022547111A (ja) 2022-11-10
WO2021044362A1 (en) 2021-03-11
KR20220058588A (ko) 2022-05-09
AR119905A1 (es) 2022-01-19
CN114341195A (zh) 2022-04-12
PH12022550538A1 (en) 2023-03-20
CN118812727A (zh) 2024-10-22
BR112022003745A2 (pt) 2022-05-31
JP2022547050A (ja) 2022-11-10
CO2022002567A2 (es) 2022-04-08
JP2022547051A (ja) 2022-11-10
CN119285791A (zh) 2025-01-10
CO2022002545A2 (es) 2022-04-08
CN118667031A (zh) 2024-09-20
MX2022002638A (es) 2022-03-25
CU20220016A7 (es) 2022-10-11
AU2020340618B2 (en) 2025-01-23
ECSP22016180A (es) 2022-04-29
CA3152500A1 (en) 2021-03-11
CU20220015A7 (es) 2022-10-11
JOP20220058A1 (ar) 2023-01-30
AR119902A1 (es) 2022-01-19
PE20221051A1 (es) 2022-06-30
IL290618A (en) 2022-04-01
AU2020343926B2 (en) 2024-11-21
CN118772293A (zh) 2024-10-15
PE20220401A1 (es) 2022-03-22
CR20220096A (es) 2022-05-11
US20230220048A1 (en) 2023-07-13
CN114341194A (zh) 2022-04-12
ZA202201828B (en) 2023-10-25
KR20220058586A (ko) 2022-05-09
EP4025239A1 (en) 2022-07-13
EP4025237A1 (en) 2022-07-13
AU2020343512A1 (en) 2022-04-07
TW202122415A (zh) 2021-06-16
ECSP22016558A (es) 2022-04-29
KR20220058585A (ko) 2022-05-09
ZA202201827B (en) 2023-11-29
AU2020340618A1 (en) 2022-04-07
MX2022002637A (es) 2022-03-25
US20230308835A1 (en) 2023-09-28
PH12022550539A1 (en) 2023-03-20
CN118909136A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
JOP20220055A1 (ar) بروتينات اندماج علاجية
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2024010140A (es) Nuevos metodos.
SA518400460B1 (ar) مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CY1124922T1 (el) Καινοτομος σταθερη φαρμακοτεχνικη μορφη για αντισωματα fxia
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12021550872A1 (en) Therapeutic compounds
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
MX2020009305A (es) Uso de un anticuerpo anti-p-selectina.
EA201792170A1 (ru) Производные индола
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
WO2017075484A3 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин
EA202191103A1 (ru) Терапевтические соединения
EA202090512A1 (ru) Пиразолопиримидиноновые соединения и их применения
EA201992754A1 (ru) Фармацевтические композиции
EA201892354A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ β-БЛОКАТОР, ИНГИБИТОР ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА И ГИПОТЕНЗИВНОЕ СРЕДСТВО ИЛИ НПВС
TH150110A (th) C3b แอนติบอดี และวิธีการสำหรับการป้องกันและการบำบัดความผิดปกติที่เกี่ยวข้องกับคอมพลีเมนท์